Syneron to Present the New GentleMax Pro(R) at the 2012 South Beach Symposium
14 Febrero 2012 - 11:30AM
Marketwired
Syneron Medical Ltd. (NASDAQ: ELOS), www.syneron.com, the global
leader in medical aesthetic products and technology, will launch
the much anticipated GentleMax Pro® at the 2012 South Beach
Symposium at the Lowes Miami Beach Hotel in Miami, Florida on
February 16 - 20, 2012. GentleMax Pro® is a solid state, dual
wavelength laser platform that offers the maximum performance in
speed and reliability for the largest energy-based, nonsurgical
cosmetic procedure -- laser hair removal.
"Building upon the solid reputation and Gold Standard technology
of the Gentle Family of lasers, the challenge we set for GentleMax
Pro was simple -- to design the next generation device that will
outperform the current Gold Standard in high-speed laser hair
removal," said Louis P. Scafuri, Chief Executive Officer of Syneron
Medical and Candela Corporation. "Not only is the GentleMax Pro
smaller, lighter and faster but we've added over a dozen new
features and refined existing features to the finest detail
starting with the way it sounds all the way up to how fast it works
-- making it a more thorough and truly enhanced experience for our
customers and their patients."
Redesigned from the ground up, the GentleMax Pro delivers robust
performance with high reliability for the busy professional hair
removal and aesthetic treatment environments. "When it comes to
offering fast and effective laser hair removal every specification
matters," said Ellen H. Frankel, M.D., dermatologist and Medical
Director at Rejuvaderm Medi Spa in Cranston, Rhode Island. "The
dual wavelength of the GentleMax Pro allows us to treat a wider
range of patients with one device and having the industry's largest
spot size of 18mm with tremendous fluence option and pulse width
range puts a whole new meaning behind high-speed laser hair
removal."
In addition to many of the system refinements, the GentleMax Pro
also comes equipped with the multi-spot Specialty Delivery System,
providing the option to treat facial veins, leg veins and other
vascular lesions including hemangioma and port wine stains with
1.5, 3.0 and 3x10 mm treatment spots. "At the Gold Laser Academy
(www.goldlaseracademy.com) we make certain to provide our attendees
with in-depth, hands-on, training utilizing all the Gold Standard
and cutting edge technologies in aesthetics," said Alan Gold, M.D.,
plastic surgeon and Director of the Gold Laser Academy in Syosset,
New York. "The GentleMax Pro has been a great addition to our
armamentarium -- all of the users from trainers to attendees have
been very impressed with the performance and versatility of the
device."
Attendees at the 2012 South Beach Symposium will be first to see
the new Gold-Standard in laser hair removal. Demonstration of the
new GentleMax Pro will occur throughout the symposium including
expert physician advice by Daniel Wasserman, M.D., board certified
Dermatologist in Napels, Florida, on Saturday, February 18, 2012
from 4pm - 4:20pm ET at the Syneron-Candela booth.
For more information about Syneron-Candela's broad product
offering, visit www.syneron.com.
About Syneron Medical Ltd. Syneron Medical
Ltd. -- a company devoted to real technology, real science and real
results -- is the leading global aesthetic device company with a
comprehensive product portfolio and a global distribution
footprint. The Company's technology enables physicians to provide
advanced solutions for a broad range of medical-aesthetic
applications including body contouring, hair removal, wrinkle
reduction, rejuvenation of the skin's appearance through the
treatment of superficial benign vascular and pigmented lesions, and
the treatment of acne, leg veins and cellulite. The Company sells
its products under two distinct brands, Syneron and Candela. The
Company's aspiration and commitment to innovation expands Syneron's
offering beyond medical device into the largest in-demand
applications in beauty -- skin lightening. Founded in 2000, the
corporate, R&D, and manufacturing headquarters for Syneron
Medical Ltd. are located in Israel. Syneron also has R&D and
manufacturing operations in the US. The company markets and
services and supports its products in 86 countries. It has offices
in North America, France, Germany, Italy, Portugal, Spain, UK,
Australia, China, Japan, and Hong Kong and distributors worldwide.
Additional information can be found at www.syneron.com.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS Any statements
contained in this document regarding future expectations, beliefs,
goals, plans or prospects constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act
of 1995. Further, any statements that are not statements of
historical fact (including statements containing "believes,"
"anticipates," "plans," "expects," "may," "will," "would,"
"intends," "estimates" and similar expressions) should also be
considered to be forward-looking statements. There are a number of
important factors that could cause actual results or events to
differ materially from those indicated by such forward-looking
statements, including the risk that the businesses of Syneron and
Candela may not be integrated successfully; the risk that the
merger transaction with Candela may involve unexpected costs or
unexpected liabilities; the risk that synergies from the merger
transaction may not be fully realized or may take longer to realize
than expected; the risk that disruptions from the merger
transaction make it more difficult to maintain relationships with
customers, employees, or suppliers; as well as the risks set forth
in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F,
and the other factors described in the filings that Syneron Medical
Ltd. makes with the SEC from time to time. If one or more of these
factors materialize, or if any underlying assumptions prove
incorrect, Syneron Medical Ltd.'s actual results, performance or
achievements may vary materially from any future results,
performance or achievements expressed or implied by these
forward-looking statements.
In addition, the statements in this document reflect the
expectations and beliefs of Syneron Medical Ltd. as of the date of
this document. Syneron Medical Ltd. anticipates that subsequent
events and developments will cause its expectations and beliefs to
change. However, while Syneron Medical Ltd. may elect to update
these forward-looking statements publicly in the future, it
specifically disclaims any obligation to do so. The forward-looking
statements of Syneron Medical Ltd. do not reflect the potential
impact of any future dispositions or strategic transactions that
may be undertaken. These forward-looking statements should not be
relied upon as representing Syneron Medical Ltd.'s views as of any
date after the date of this document.
Contacts: Syneron - Public Relations Email Contact Asaf
Alperovitz Chief Financial Officer + 972 73 244 2283 Zack Kubow The
Ruth Group 646-536-7020
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024